SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma advances on receiving final approval from USFDA for Azacitidine for Injection

27 Jun 2017 Evaluate

Natco Pharma is currently trading at Rs. 979.70, up by 7.20 points or 0.74% from its previous closing of Rs. 972.50 on the BSE.

The scrip opened at Rs. 1009.00 and has touched a high and low of Rs. 1009.00 and Rs. 975.00 respectively. So far 6,590 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1080.00 on 09-Jun-2017 and a 52 week low of Rs. 495.00 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 1009.00 and Rs. 963.00 respectively. The current market cap of the company is Rs. 17,076.00 crore.

The promoters holding in the company stood at 51.24%, while Institutions and Non-Institutions held 26.70% and 22.05% respectively.

Natco Pharma has received final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) for Azacitidine for Injection, 100mg per Vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation.

NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in the near future.

Vidaza is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). Vidaza generated total combined sales of $188 million for the twelve-month period ending April, 2017, based on industry sales data.


Natco Pharma Share Price

1118.95 31.25 (2.87%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×